Methods for treating a stricture with a botulinum toxin
Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating the urethra stricture.
1 . A method for treating a urethral stricture in a patient, the method comprising the step of administering an effective amount of a botulinum toxin directly to a urethra of the patient, wherein the patient is having or has had a stenting procedure, thereby treating the urethral stricture.
2 . The method of claim 1 wherein the step of administering includes injecting the botulinum toxin into a wall of the urethra.
3 . The method of claim 1 wherein the step of administering is accomplished using a stent coated or impregnated with the botulinum toxin.
4 . The method of claim 1 wherein the botulinum toxin reduces or eliminates a damage to the urethra that is due to the stenting procedure.
5 . The method of claim 1 wherein the botulinum toxin reduces or eliminates a damage to the urethra by reducing the recurrence of the stricture.
6 . The method of claim 1 wherein the botulinum toxin reduces or eliminates a damage to the urethra by preventing the urethral epithelium from covering the stent.
7 . The method of claim 1 wherein the botulinum toxin reduces or eliminates a damage to the urethra by preventing the stent from becoming incorporated into the urethral wall.
8 . The method of claim 1 wherein the botulinum toxin reduces or eliminates a damage to the urethra by reducing or eliminating bleeding in the urethra.
9 . The method of claim 1 wherein the botulinum toxin reduces or eliminates damage to the urethra by reducing or eliminating extravasation of irrigation fluid into perispongial tissues.
10 . The method of claim 1 wherein the botulinum toxin reduces or eliminates damage to the urethra by preventing an increase in fibrotic response.
11 . The method of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
12 . The method of claim 1 wherein the botulinum toxin is botulinum toxin type A.
13 . A method for treating a urethral stricture in a mammal, the method comprising the step of
(a) administering an effective amount of a botulinum toxin directly to a urethra of the mammal; and
(b) stenting the urethra.
14 . The method of claim 13 wherein the administering includes the step of injecting the botulinum toxin into a wall of the urethra.
15 . The method of claim 13 wherein the step of administering is accomplished using a stent coated or impregnated with the botulinum toxin.
16 . The method of claim 13 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
17 . The method of claim 13 wherein the botulinum toxin is botulinum toxin type A.
18 . A method for treating a urethral stricture in a patient, the method comprising the step of administering an effective amount of a botulinum toxin directly to a urethra of the patient, wherein the patient is not having a urethrotomy, thereby treating the urethral stricture.
19 . The method of claim 18 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
20 . The method of claim 18 wherein the botulinum toxin is botulinum toxin type A.
21 . A method for treating a urethral stricture, the method comprising the step of inserting into a urethral stricture of a patient a biodegradable stent coated with or embedded with a therapeutically effective amount of a botulinum toxin, thereby treating the urethral stricture.